Recent Transactions

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

14-Feb-24
Undisclosed
United Kingdom flag
Target: 

Huntswood CTC Limited

Acquiror: 
The Results Companies, LLC

Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital

04-Sep-23
Pending
$6.6 billion AUD
Australia flag
Target: 

Liontown Resources Limited

United States flag
Acquiror: 
Albemarle Corporation

Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

13-Jul-23
$224 million
Target: 

Distribuidora Internacional Carmen SAU

United States flag
Acquiror: 
Diploma PLC

Advised Diploma PLC in the acquisition of  Distribuidora Internacional Carmen SAU (“DICSA”),  a market-leading distributor of fluid power solutions into the European aftermarket

01-Jun-23
$90.4 million
Canada flag
Target: 

PCAS Canada Inc.

Japan flag
Acquiror: 
DIC Corporation

Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens

27-Apr-23
$403 million
Netherlands flag
Target: 

Distrelec BV

United Kingdom flag
Acquiror: 
RS Group plc

Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products

26-Apr-23
Pending
$127 million
Australia flag
Target: 

Marley Spoon business combination with 468 SPAC II

Germany flag
Acquiror: 
468 SPAC II SE

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

05-Apr-23
Pending
$185 million
Australia flag
Target: 

Calibre Group’s QuadR Business

Canada flag
Acquiror: 
WSP Global Inc.

Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

07-Mar-23
Undisclosed
United Kingdom flag
Target: 

David Brown Santasalo

United States flag
Acquiror: 
Stellex Capital Management

Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

30-Nov-22
Pending
Undisclosed
Australia flag
Target: 

Calibre Group’s Built Environment Business

France flag
Acquiror: 
Egis S.A.

Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts

28-Nov-22
Pending
$650 million
Australia flag
Target: 

Brambles (CHEP China)

China flag
Acquiror: 
Loscam Greater China

Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

18-Nov-22
Pending
$6.4 billion
Australia flag
Target: 

OZ Minerals Limited

Australia flag
Acquiror: 
BHP Group Limited

Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company

13-Sep-22
Undisclosed
United Kingdom flag
Target: 

InterGen N.V.’s UK business

Czech Republic
Acquiror: 
Bortela Capital s.r.o

Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic

28-Jul-22
Pending
$1.6 billion
Chile Flag
Target: 

Derco Holdings

United Kingdom flag
Acquiror: 
Inchcape Plc

Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America

04-Jul-22
$270 million
France flag
Target: 

Vulcanic

United Kingdom flag
Acquiror: 
Spirax-Sarco Engineering plc

Advised Spirax-Sarco Engineering plc, a thermal energy management and niche pumping specialist, on the $270m acquisition of Vulcanic, a French industrial electric heating group and the largest supplier in Europe of bespoke industrial electric heating solutions

30-Jun-22
~$210 million
Australia flag
Target: 

Liontown Resources

United States flag
Acquiror: 
Offtake Agreement and Financing Facility from Ford Motor Company

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company

04-Apr-22
Pending
~$230 million
Australia flag
Target: 

DGO Gold

Australia flag
Acquiror: 
Gold Road Resources

Advising DGO Gold, an ASX-listed gold exploration company, on its recommended, off-market takeover offer from Gold Road Resources, an ASX-listed gold producer

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Pages

show all